UPDATE: Deutsche Bank Reiterates on Aegerion Pharmaceuticals Following Company Analyst Day
November 13, 2013 at 10:23 AM EST
In a report published Wednesday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR ), and raised the price target from $107.00 to $115.00. In the report, Deutsche Bank noted, “Following the Aegerion analyst day and our recent channel checks we are increasing our 2014
